Core Insights - Kyowa Kirin has appointed Abdul Mullick, Ph.D., as the new President and CEO, effective March 2026, while current CEO Masashi Miyamoto will remain as Chairman [1][2][3] Leadership Transition - The company approved a dual CEO/COO model in March 2025, allowing Mullick to gain insights as the first non-Japanese CEO [2] - The transition back to a single leader model aims to create a more agile management structure to respond to global business changes [3] Strategic Focus - As CEO, Mullick will drive the execution of the company's Vision for 2030, focusing on Bone/Mineral, Intractable Haematological Diseases/Haemato-Oncology, and Rare Diseases [3][4] Mullick's Background - Mullick joined Kyowa Kirin in 2017 and has held various leadership roles, including President of the Europe/Middle East/Africa region and COO [4][5] - He has a Ph.D. in Molecular Biology from the University of Bristol and a BSc from Kingston University, both in the UK [5] Company Mission - Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value, focusing on high unmet medical needs [6]